Black Diamond Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a leader in precision oncology, announced that CEO David M. Epstein will present at two upcoming investor conferences. The presentations are scheduled for August 12, 2020, at the Wedbush PacGrow Healthcare Conference and August 13, 2020, at the Canaccord Genuity Growth Conference. Live webcasts will be available on the company’s website, with replays archived for three weeks. Black Diamond focuses on developing tumor-agnostic therapies targeting undrugged mutations in genetically defined cancers.

CAMBRIDGE, Mass. and NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Company’s progress at the following upcoming investor conferences:

• The 2020 Wedbush PacGrow Healthcare Conference. The presentation will take place on Wednesday, August 12, 2020, at 10:20 AM ET.
• The 40^th Annual Canaccord Genuity Growth Conference. The presentation will take place on Thursday, August 13, 2020, at 3:30 PM ET.

Live webcasts of each presentation can be accessed by visiting the investor relations section of the Company’s website, www.blackdiamondtherapeutics.com. A replay of each presentation will also be available and archived on the site for three weeks.

About Black Diamond
Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, tumor-agnostic therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Company’s proprietary technology platform, Mutation-Allostery-Pharmacology, or MAP, platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families, and develop a single small molecule therapy in a tumor-agnostic manner that targets a specific family of mutations. Black Diamond was founded by David M. Epstein, Ph.D., and Elizabeth Buck, Ph.D., and, beginning in 2017, together with Versant Ventures, began building the MAP platform and chemistry discovery engine. For more information, please visit www.blackdiamondtherapeutics.com.

Contacts:

For Investors:
Natalie Wildenradt
investors@bdtherapeutics.com

For Media:
Kathy Vincent
(310) 403-8951
media@bdtherapeutics.com

FAQ

When will Black Diamond Therapeutics present at the Wedbush PacGrow Healthcare Conference?

Black Diamond Therapeutics will present on August 12, 2020, at 10:20 AM ET.

What is the date for Black Diamond Therapeutics' presentation at the Canaccord Genuity Growth Conference?

The presentation at the Canaccord Genuity Growth Conference is scheduled for August 13, 2020, at 3:30 PM ET.

Where can I access the live webcast of Black Diamond Therapeutics' presentations?

Live webcasts of the presentations can be accessed on Black Diamond Therapeutics' investor relations website.

What technology platform does Black Diamond Therapeutics use?

Black Diamond Therapeutics uses the Mutation-Allostery-Pharmacology (MAP) platform to develop tumor-agnostic therapies.

What is the primary focus of Black Diamond Therapeutics?

Black Diamond Therapeutics focuses on discovering and developing small molecule, tumor-agnostic therapies for genetically defined cancers.